ArticleMultiple sclerosis (Houndmills, Basingstoke, England)2022

The MSIS-29 and SF-36 as outcomes in secondary progressive MS trials.

Eva Mm Strijbis et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.